
The results of a study that looked at the competing effects on left ventricular hypertrophy (LVH) of hypokalemia and treatment with hydrochlorothiazides (HCTZ) in hypertensive patients were presented Monday, November 15 at the American Heart Association Scientitifc Sessions 2009.
Although treatment with low-dose aspirin is standard care for secondary prevention of cardiovascular (CV) events, some studies have shown that up to half of all patients stop taking aspirin. Other studies have shown that discontinuation of aspirin in these patients is linked to an increased risk of MI and other ischemic events.
Do women face a higher risk of death compared with men following treatment with primary percutaneous coronary intervention (PCI) following ST elevation myocardial infarction (STEMI)? A study presented during the "Women, STEMI, and PCI Trials" Abstract Oral Session Tuesday morning at the American Heart Association Scientific Sessions 2009 sought to answer that question.
Although previous studies have shown that women are less likely to receive acute reperfusion treatment for ST elevation myocardial infarction (STEMI) in clinical practice, there is comparatively little data on "gender differences in adjunctive treatment and outcome in the setting of primary PCI." Given this lack of data, what is the impact of female gender on hospital outcome of primary percutaneous coronary intervention (PCI) in patients with STEMI in clinical practice?
Does the evidence support the guidelines that recommend immediate reperfusion therapy for patients presenting with a new or presumed new left bundle branch block (LBBB)? A study presented during the "Women, STEMI, and PCI Trials" Abstract Oral Session Tuesday morning at the American Heart Association Scientific Sessions 2009 provided a surprising answer to that question.
Does adherence to ACC/AHA guideline therapies in patients with non-ST-elevation myocardial infarction (NSTEMI) result in reductions in one-year post-discharge mortality rates?
Results from several interesting studies that looked at efforts to decrease door-to-balloon time in ST-elevation myocardial infarction (STEMI) and whether time reductions had any effect on mortality rates were presented during abstract poster sessions and abstract oral sessions Monday and Tuesday at the American Heart Association Scientific Sessions 2009.
A study presented Tuesday at the American Heart Association Scientific Sessions 2009 looked at the relationship between coronary micro-vessel spasm, epicardial coronary artery spastic angina, and non-obstructive coronary artery disease.
Study results from the MERLIN-TIMI 36 Trial looking at the risk of ischemia and nonsustained ventricular tachycardia (NSVT) alone or combined in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) were presented during an abstract oral session at the American Heart Association Scientific Sessions 2009.

American Journal of Pharmacy Benefits
HCPLive
ONCLive
OTCGuide
Pharmacy Times
Physician's Money Digest
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.
